Trials / Completed
CompletedNCT01333007
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 423 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.
Conditions
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2011-04-11
- Last updated
- 2016-11-02
Locations
152 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01333007. Inclusion in this directory is not an endorsement.